Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA

INTRODUCTION: Sotrovimab, a recombinant human monoclonal antibody (mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had US Food and Drug Administration Emergency Use Authorization for the treatment of high-risk outpatients with mild-to-moderate coronavirus disease 2019 (COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Mindy M., Reyes, Carolina, Satram, Sacha, Birch, Helen, Gibbons, Daniel C., Drysdale, Myriam, Bell, Christopher F., Suyundikov, Anvar, Ding, Xiao, Maher, M. Cyrus, Yeh, Wendy, Telenti, Amalio, Corey, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832411/
https://www.ncbi.nlm.nih.gov/pubmed/36629998
http://dx.doi.org/10.1007/s40121-022-00755-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832411/
https://www.ncbi.nlm.nih.gov/pubmed/36629998
http://dx.doi.org/10.1007/s40121-022-00755-0

Ejemplares similares